Navigation Links
Preclinical data shows 100 percent prevention and treatment of influenza with engineered human antibody
Date:9/10/2012

Cambridge, MA September 10, 2012 Visterra, Inc., developer of novel therapeutics to treat major diseases, today announced the presentation of positive data from a preclinical study evaluating the efficacy of the company's lead product candidate, VIS410, a broadly protective, fully human monoclonal antibody being developed for influenza A infections. Data from preclinical studies were presented today at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco. These data were also selected by ICAAC to be included in the public communication highlights for the meeting.

Developed using Visterra's innovative platform, VIS410 targets a site on influenza hemagglutinin (HA) that is present across all influenza A subtypes and is resistant to mutation development. VIS410 demonstrated broad neutralization against all influenza A strains tested in vitro, and provided potent and specific protection in mouse models against a lethal dose of influenza A virus, both prophylactically and therapeutically. In prophylactic studies, 100% of healthy non-infected mice who received a single dose of VIS410 survived subsequent infection with either H1N1 or H3N2 influenza A virus. In post-infection therapeutic studies, 100% of mice treated with a single dose of VIS410 survived a lethal viral challenge of either H1N1 or H3N2 when antibody was administered up to 72 hours after infection.

"This data with VIS410 shows several ways that this drug candidate has promise for fighting influenza, including possible pandemic strains," said Donna Ambrosino, M.D., Chief Medical Officer of Visterra. "With VIS410, we have designed an antibody that targets the viral hemagglutinin protein (HA) to enable to healthy person or patient to prevent or treat an established infection. Secondly, we have designed VIS410 as an antibody that neutralizes both groups of viral strains for influenza A, Group 1 and Group 2 viruses, opening the pot
'/>"/>

Contact: Kathryn Morris
kathryn@theyatesnetwork.com
845-635-9828
The Yates Network
Source:Eurekalert

Page: 1 2 3 4

Related biology technology :

1. Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
2. MultiCell Technologies Announces Positive Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer In Vitro Models
3. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
4. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
5. Survey Shows Physicians Divided as Presidential Election Nears
6. Science study shows promiscuous enzymes still prevalent in metabolism
7. Study Shows Transition to Practice Programs Get Nurses Employed
8. Study shows availability of hydrogen controls chemical structure of graphene oxide
9. CSL Behring Data Shows 4-Factor Prothrombin Complex Concentrate Is As Effective and a More Rapid Treatment for Vitamin K Antagonist Reversal Than Current Standard of Care
10. New Revolutionary Femoral Access Site Closure Device Shows Unparalleled Efficacy, Safety & Ease of Use, in a Wide Range of Patients Including Patients With a Challenging Anatomy
11. Pharmacoeconomic Analysis Shows SURFAXIN® May Reduce Hospital Cost Associated with Reintubation in Premature Infants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology ... difficult to manufacture proteins including biosimilar therapeutics, today ... for the second quarter ended June 30, 2014. ... initial public offering, we have the capital to ... from our proprietary protein expression platform," stated Bertrand ...
(Date:8/29/2014)... VANCOUVER , Aug. 29, 2014 /PRNewswire/ - ... (OTCQX: ICOTF), today reported financial results for the ... specified otherwise, are expressed in Canadian dollars and ... Second Quarter 2014 Highlights , ... visual acuity (VA) primary endpoint for subjects enrolled ...
(Date:8/29/2014)... San Antonio, TX (PRWEB) August 29, 2014 ... 9001:2008 and ISO 13485:2003 certified, GAMP® 5 compliant ... been awarded an international Phase II clinical trial ... non-Hodgkin’s lymphoma. , Throughout this trial, Intrinsic Imaging ... but not limited to, protocol and charter development, ...
(Date:8/28/2014)... new research platform uses a laser to ... undergoing stress and heating, an approach likely ... microelectronics and batteries., This new technique, called ... heating and the surface stress of microscale ... discussed the merits of surface-stress influence on ...
Breaking Biology Technology:Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3
... 31 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc.,(Nasdaq: CHBT ... in the manufacture, research, development, marketing and,distribution of ... four patents to the State Intellectual Property Office ... These applications are patents for a ...
... Ueno, Ltd. announced on July 29 after discussing its R&D policy ... day and determined the R&D items as follows. , , ... ophthalmologic & dermatological fields that are its priority and exclusive areas, ... 1. Development code UF-021 (eye diseases) , , ...
... , , PHILADELPHIA, July 30 eResearchTechnology, Inc. (ERT), ... and other services to the biopharmaceutical, medical device and related industries, announced ... 2009. Unless otherwise noted, all comparative numbers refer to changes from ... , Highlights of the second quarter of 2009 were: ...
Cached Biology Technology:China-Biotics, Inc. Applies for Four Patents on Probiotic Formulations 2China-Biotics, Inc. Applies for Four Patents on Probiotic Formulations 3R-Tech Ueno Notifies R&D Items 2R-Tech Ueno Notifies R&D Items 3ERT Reports Second Quarter 2009 Results 2ERT Reports Second Quarter 2009 Results 3ERT Reports Second Quarter 2009 Results 4ERT Reports Second Quarter 2009 Results 5ERT Reports Second Quarter 2009 Results 6ERT Reports Second Quarter 2009 Results 7ERT Reports Second Quarter 2009 Results 8ERT Reports Second Quarter 2009 Results 9ERT Reports Second Quarter 2009 Results 10ERT Reports Second Quarter 2009 Results 11ERT Reports Second Quarter 2009 Results 12
(Date:8/29/2014)... Until recently, little has been known about what genetic ... team of scientists, one of whom is a University ... showing that genes controlling the development of the brain ... domestication., The study was published Aug. 28 in ... It is online at http://www.sciencemag.org/ ., The domestication ...
(Date:8/29/2014)... available in German . ... organisms is considered the oldest form of communication. Acting ... for example, the sexual attraction between males and females. ... to coordinate reproductive behavior in males and females. Scientists ... the Algarve in Faro, Portugal, and at the Max ...
(Date:8/28/2014)... Invasives is now available from the Lady Bird Johnson ... for identifying harmful non-native plant, insect and other invasive ... States cause about $137 billion in economic and other ... kill native plants and more. , "By having streamlined ... invasive species occur, we,re more likely to catch these ...
Breaking Biology News(10 mins):New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3Ready for mating at the right time 2Ready for mating at the right time 3Mobile app makes ID of harmful plants, insects in Texas a snap 2
... called nestin to a particularly deadly form of breast ... earlier detection and better treatment. , In the ... Medical School demonstrate that nestin could represent a selective ... aggressive cancer with similarities to mammary stem cells, the ...
... long term hip replacement surgery may lie in the genes, ... the Rheumatic Diseases. , The researchers analysed genetic variations in ... after hip replacement in the 10 years following surgery. ... “aseptic loosening,?which describes a condition in which the artificial joint ...
... leopard found on the islands of Borneo and Sumatra is ... was originally thought to be the same species as the ... analysis conducted at the U.S. National Cancer Institute shows that ... to the differences between other large cat species like lions, ...
Cached Biology News:Selective marker found to indicate aggressive form of breast cancer 2New species declared: Clouded leopard on Borneo and Sumatra 2
... IT siRNA Tracker Intracellular Localization Kit provides ... and deliver siRNA, of your design, in ... vitro tracking experiments. Subcellular localization and functional ... monitored following introduction of the labeled siRNA ...
... Beacon 2000 instrument can be used as ... 2000 Data Manager Software provides the means ... from the instrument. These data can then ... spreadsheets, such as Microsoft Excel or Lotus ...
... for the study of protein:protein interactions from ... that interact with GST•Tag™, S•Tag™, or ... using affinity resins for the tags, and ... filter. The complexes are eluted with sample ...
... Microarray Kit (V2), 22K is useful for investigating ... Each microarray contains content derived from the ATH1 ... Research (TIGR) and represents 21,500 genes. ... x 3? glass slides each containing an identical ...
Biology Products: